M. Franco G. Salvoza

Array ( [id] => 15931867 [patent_doc_number] => 20200157567 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-21 [patent_title] => Viral Vector [patent_app_type] => utility [patent_app_number] => 16/604362 [patent_app_country] => US [patent_app_date] => 2018-04-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10183 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 79 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16604362 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19650043 [patent_doc_number] => 12171803 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-12-24 [patent_title] => Methods of CD40 and toll like receptor immune activation [patent_app_type] => utility [patent_app_number] => 16/604818 [patent_app_country] => US [patent_app_date] => 2018-04-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 14283 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 88 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16604818 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15765961 [patent_doc_number] => 20200113998 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-16 [patent_title] => HBV VACCINE [patent_app_type] => utility [patent_app_number] => 16/604221 [patent_app_country] => US [patent_app_date] => 2018-04-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12841 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16604221 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16176937 [patent_doc_number] => 20200223905 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-16 [patent_title] => Anti-Influenza B Virus Neuraminidase Antibodies And Uses Thereof [patent_app_type] => utility [patent_app_number] => 16/500628 [patent_app_country] => US [patent_app_date] => 2018-04-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 100044 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -72 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16500628 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13590671 [patent_doc_number] => 20180346884 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-06 [patent_title] => MODIFIED HUMAN ROTAVIRUSES AND USES THEREFOR [patent_app_type] => utility [patent_app_number] => 15/947649 [patent_app_country] => US [patent_app_date] => 2018-04-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12203 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15947649 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17421270 [patent_doc_number] => 11254712 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-02-22 [patent_title] => Chimeric molecules and uses thereof [patent_app_type] => utility [patent_app_number] => 16/498865 [patent_app_country] => US [patent_app_date] => 2018-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 21 [patent_no_of_words] => 35536 [patent_no_of_claims] => 33 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16498865 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17937090 [patent_doc_number] => 11471522 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-10-18 [patent_title] => Methods and compositions for stimulating immune response [patent_app_type] => utility [patent_app_number] => 16/496858 [patent_app_country] => US [patent_app_date] => 2018-03-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 24 [patent_no_of_words] => 28906 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16496858 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16761097 [patent_doc_number] => 20210106678 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-15 [patent_title] => IMMUNITY-INDUCING AGENT AND PHARMACEUTICAL COMPOSITION CONTAINING SAME [patent_app_type] => utility [patent_app_number] => 16/498374 [patent_app_country] => US [patent_app_date] => 2018-03-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5775 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16498374 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15496921 [patent_doc_number] => 20200048649 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-13 [patent_title] => VIRUS-LIKE PARTICLES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/492619 [patent_app_country] => US [patent_app_date] => 2018-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30347 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16492619 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13300741 [patent_doc_number] => 20180201907 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-19 [patent_title] => METHODS FOR INCREASING THE INFECTIVITY OF VIRUSES [patent_app_type] => utility [patent_app_number] => 15/920191 [patent_app_country] => US [patent_app_date] => 2018-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14601 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -112 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15920191 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15360967 [patent_doc_number] => 20200016248 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-16 [patent_title] => TREATMENT OF PRURITUS IN HORSES [patent_app_type] => utility [patent_app_number] => 16/491514 [patent_app_country] => US [patent_app_date] => 2018-03-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34536 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16491514 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18070593 [patent_doc_number] => 11529409 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-12-20 [patent_title] => Influenza B virus mutants and uses therefor [patent_app_type] => utility [patent_app_number] => 16/488913 [patent_app_country] => US [patent_app_date] => 2018-02-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 36 [patent_no_of_words] => 23504 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16488913 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16236851 [patent_doc_number] => 20200254085 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-13 [patent_title] => IMMUNOGENIC COMPOSITIONS AGAINST INFLUENZA [patent_app_type] => utility [patent_app_number] => 16/488906 [patent_app_country] => US [patent_app_date] => 2018-02-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18963 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16488906 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13870835 [patent_doc_number] => 20190031758 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-31 [patent_title] => COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFECTIONS AND TUMORS [patent_app_type] => utility [patent_app_number] => 15/898108 [patent_app_country] => US [patent_app_date] => 2018-02-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46905 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15898108 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18574295 [patent_doc_number] => 11730801 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-08-22 [patent_title] => Live attenuated Zika virus with 3'UTR deletion, vaccine containing and use thereof [patent_app_type] => utility [patent_app_number] => 16/485818 [patent_app_country] => US [patent_app_date] => 2018-02-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 93 [patent_no_of_words] => 21660 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16485818 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13354763 [patent_doc_number] => 20180228921 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-16 [patent_title] => VISUALIZING VIRAL RESERVOIRS AND DISSEMINATION IN VIVO [patent_app_type] => utility [patent_app_number] => 15/895414 [patent_app_country] => US [patent_app_date] => 2018-02-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3390 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15895414 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16756819 [patent_doc_number] => 10975359 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-04-13 [patent_title] => Retargeting of viruses or VLPs [patent_app_type] => utility [patent_app_number] => 16/482771 [patent_app_country] => US [patent_app_date] => 2018-02-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 6 [patent_no_of_words] => 16962 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 154 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16482771 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15228089 [patent_doc_number] => 10501758 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-12-10 [patent_title] => Recombinant baculovirus and method for using the same for preparing recombinant adeno-associated virus vector [patent_app_type] => utility [patent_app_number] => 15/884470 [patent_app_country] => US [patent_app_date] => 2018-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 15 [patent_no_of_words] => 4242 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 86 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15884470 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16877998 [patent_doc_number] => 11028131 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-06-08 [patent_title] => Mutant of adeno-associated virus (AAV) capsid protein [patent_app_type] => utility [patent_app_number] => 16/481159 [patent_app_country] => US [patent_app_date] => 2018-01-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 2 [patent_no_of_words] => 9719 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 95 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16481159 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14160871 [patent_doc_number] => 20190107538 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-11 [patent_title] => EVALUATION OF THE SEVERITY OF PATIENTS WITH FLAVIVIRUS INFECTION BY BLOOD HYALURONAN LEVELS AND THERAPEUTIC AGENTS TO BLOCK THE HYALURONAN [patent_app_type] => utility [patent_app_number] => 15/881350 [patent_app_country] => US [patent_app_date] => 2018-01-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5260 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15881350 [rel_patent_id] =>[rel_patent_doc_number] =>)